Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest PharmaTechQPTFF Debt-to-Equity is 0.04 as of Jan. 2026, which is at its 10-year median of 0.04. Among 965 Biotechnology companies, Quest PharmaTech ranks better than 74.3% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Quest PharmaTech's Debt-to-Equity or its related term are showing as below:
QPTFF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.18 Med: 0.04 Max: 0.05
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of Quest PharmaTech was 0.05. The lowest was -0.18. And the median was 0.04.
QPTFF's Debt-to-Equity is ranked better than 74.3% of 965
companies
in the Biotechnology industry
Industry Median: 0.15
vs QPTFF: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Quest PharmaTech Debt-to-Equity Related Terms
Quest PharmaTech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Quest PharmaTech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QPTFF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Quest PharmaTech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest PharmaTech Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quest PharmaTech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Quest PharmaTech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest PharmaTech (QPTFF) has a Debt-to-Equity of 0.04 as of Jan. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Quest PharmaTech and its competitors. This is near median its historical median of 0.04. According to the industry distribution chart, Quest PharmaTech ranks #248 out of 965 companies in the Biotechnology industry, placing it in the top 25.7%.
Is Quest PharmaTech's Debt-to-Equity too high?
Quest PharmaTech's current Debt-to-Equity of 0.04 is near median its 10-year median of 0.04. The Biotechnology industry median Debt-to-Equity is 0.15. Quest PharmaTech's value of 0.04 is 73.3% below this industry median. Based on the distribution chart, Quest PharmaTech ranks #248 out of 965 companies in the Biotechnology industry, which is above the industry midpoint.
How does Quest PharmaTech's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Quest PharmaTech ranks #248 out of 965 companies for Debt-to-Equity. This puts Quest PharmaTech in the upper half of its industry. The industry median Debt-to-Equity is 0.15. Quest PharmaTech's value of 0.04 is 73.3% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.15, Quest PharmaTech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest PharmaTech's current Debt-to-Equity of 0.04 is 73.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Quest PharmaTech and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest PharmaTech's current Debt-to-Equity is 0.04, which is near median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest PharmaTech stock overvalued right now?
Quest PharmaTech (QPTFF) has a current Debt-to-Equity of 0.04. The current Debt-to-Equity is 0.04, which is near median its 10-year median of 0.04 and 73.3% below the Biotechnology industry median of 0.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Quest PharmaTech (QPTFF), the current Debt-to-Equity is 0.04 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest PharmaTech Inc is developing targeted cancer therapy with its product (MAb AR9.6), under development for a novel target (truncated O-glycans on MUC16) discovered at the University of Nebraska Medical Center.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QPTFF has been successfully added to your 
